Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Liabilities and Shareholders Equity (2023 - 2025)

Mangoceuticals' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $16.5 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 11.76% year-over-year to $16.5 million; the TTM value through Sep 2025 reached $74.5 million, up 137.39%, while the annual FY2024 figure was $15.4 million, 1362.75% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $16.5 million at Mangoceuticals, down from $20.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $21.8 million in Q1 2025 and bottomed at $301447.0 in Q1 2024.
  • The 3-year median for Liabilities and Shareholders Equity is $14.8 million (2024), against an average of $10.4 million.
  • The largest annual shift saw Liabilities and Shareholders Equity crashed 92.67% in 2024 before it surged 7116.48% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $1.1 million in 2023, then skyrocketed by 1362.75% to $15.4 million in 2024, then grew by 7.56% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Liabilities and Shareholders Equity are $16.5 million (Q3 2025), $20.8 million (Q2 2025), and $21.8 million (Q1 2025).